$BSX

Habiger David C purchased $100K of BSX

Habiger David C purchased 2,100 shares of BOSTON SCIENTIFIC CORP (BSX) at $47.59 on 2026-08-05.

Original reporting
SEC EDGAR · Habiger David C
Published Aug 7, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 8:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BSX
Neutral
low confidence
Mentioned
$BSX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BSXNeutralLow
01

Why it matters

The only disclosed new fact is the director’s open-market purchase details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may note insider buying as a mild sentiment input, but there is no accompanying fundamental or regulatory catalyst in the text.

03

What to watch

The Form 4 states no 10b5-1 plan, but the article provides no context on motivation, prior trading history, or whether the purchase size is meaningful versus typical director activity.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07 after-hours; transaction dated 2026-08-05

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Boston Scientific.

Company-level read

Ticker impact

$BSXNeutralLow confidence
Context

SEC Form 4 shows director Habiger David C bought 2,100 shares of Boston Scientific at $47.5890 on 2026-08-05.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.

Evidence & confidence

The filing is an insider buy, but it is not tied to new company guidance, contracts, litigation, or regulatory actions in the text.

Market effects

No sector read-through is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine (compensation, diversification, or pre-planned liquidity needs) and may not reflect a new bullish thesis.

Key entities

  • Boston Scientific Corp

    Subject of the Form 4 insider transaction disclosure.

  • Habiger David C

    Director who purchased 2,100 shares on 2026-08-05.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BSXMedAI 8/10

Boston Scientific stock drops on duidance cut (BSX:NYSE)

Boston Scientific (BSX) shares declined in premarket trading Wednesday despite Q3 2026 earnings beating expectations. The company reduced its full-year outlook, attributing the change to a recent cybersecurity incident. According to the company, the incident impacted its financial performance. BSX reported Q3 2026 financials but did not disclose specific figures in the provided text.

$BSXHighAI 8/10

Why is Boston Scientific stock sliding today?

Boston Scientific (BSX) shares fell 3.6% to $43.42 in pre-market trading after reporting Q3 2026 earnings. Adjusted EPS of $0.73 missed estimates by $0.02, while revenue of $5.14B exceeded expectations. The company cut Q4 and full-year 2026 EPS guidance due to a cyberattack and other challenges, citing a 1%-3% expected decline in Q4 sales.